...
首页> 外文期刊>Human Pathology >Clinicopathological comparison of colorectal and endometrial carcinomas in patients with Lynch-Like syndrome versus patients with Lynch syndrome
【24h】

Clinicopathological comparison of colorectal and endometrial carcinomas in patients with Lynch-Like syndrome versus patients with Lynch syndrome

机译:Lynch-Like综合征患者与Lynch综合征患者结直肠癌和子宫内膜癌的临床病理比较

获取原文
获取原文并翻译 | 示例
           

摘要

Screening for DNA mismatch repair (MMR) deficiency in colorectal and endometrial carcinomas identifies patients at risk for Lynch syndrome. Some patients with MMR-deficient tumors have no evidence of a germline mutation and have been described as having Lynch-like syndrome. We compared the clinicopathological features of colorectal and endometrial carcinomas in patients with Lynch-like syndrome and Lynch syndrome. Universal screening identified 356 (10.6%) of 3352 patients with colorectal carcinoma and 72 (33%) of 215 patients with endometrial carcinoma with deficient DNA MMR. Sixty-six patients underwent germline mutation analysis with 45 patients (68%) having evidence of a germline MMR gene mutation confirming Lynch syndrome and 21 patients (32%) having Lynch-like syndrome with no evidence of a gemiline mutation. Most patients with Lynch-like syndrome had carcinoma involving the right colon compared to patients with Lynch syndrome (93% versus 45%; P < .002). All patients with colorectal carcinomas demonstrating isolated loss of MSH6 expression had Lynch syndrome confirmed by germline mutation analysis. Synchronous or metachronous Lynch syndrome associated carcinoma was more frequently identified in patients with Lynch syndrome compared to Lynch-like syndrome (38% versus 7%; P = .04). There were no significant differences in clinicopathological variables between patients with Lynch-like syndrome and Lynch syndrome with endometrial carcinoma. In summary, 32% of patients with MMR. deficiency concerning Lynch syndrome will have Lynch-like syndrome. Our results demonstrate that patients with Lynch-like syndrome are more likely to have right-sided colorectal carcinoma, less likely to have synchronous or metachronous Lynch syndrome associated carcinoma, and less likely to demonstrate isolated loss of MSH6 expression within their tumor. (C) 2015 Elsevier Inc. All rights reserved.
机译:在大肠癌和子宫内膜癌中进行DNA错配修复(MMR)缺乏症的筛查可确定存在Lynch综合征风险的患者。一些患有MMR缺陷的肿瘤的患者没有种系突变的证据,已被描述为患有Lynch样综合征。我们比较了Lynch-like综合征和Lynch综合征患者大肠癌和子宫内膜癌的临床病理特征。通用筛查发现3352例大肠癌患者中有356例(10.6%)和215例子宫内膜癌DNA MMR不足的患者中有72例(33%)。六十六名患者接受种系突变分析,其中有45名患者(68%)有证实林奇综合征的种系MMR基因突变的证据,还有21名患者(32%)有无gemline突变证据的林奇样综合征。与Lynch综合征患者相比,大多数Lynch-like综合征患者的癌均累及右结肠(93%对45%; P <.002)。通过种系突变分析证实,所有表现出MSH6表达单独丧失的大肠癌患者均具有Lynch综合征。与Lynch样综合征相比,在Lynch综合征患者中更频繁地发现同步或异时Lynch综合征相关的癌(38%对7%; P = .04)。 Lynch样综合征和Lynch综合征子宫内膜癌患者的临床病理变量无显着差异。综上所述,有32%的MMR患者。与Lynch综合征有关的缺乏症将有Lynch-like综合征。我们的结果表明,患有Lynch样综合征的患者更有可能患右侧大肠癌,不太可能患有同步或异时Lynch综合征相关的癌,并且不太可能证明其肿瘤内MSH6表达的单独丧失。 (C)2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号